New study reveals blue state's fast-food minimum wage hike jeopardized thousands of jobs
A Berkeley Research Group study discovered not only were there 10,700 jobs lost between June 2023 and June 2024 in the sector, according to Bureau of Labor Statistics data. But prices at the establishments soared by 14.5% after the new minimum wage became law.
"California fast food restaurants also increased automation and technology adoption to offset rising labor costs," the study released Feb. 18 stated.
"Therefore, it should not be surprising that the number of employees per restaurant is declining.
Blue City Mayor Embraces Government Efficiency In New Memo To City Employees
"Californians are bearing the cost of the minimum wage increase through fewer available jobs and higher food cost," it added. The study also debunked notions that the minimum-wage legislation created jobs, according to the California Globe.
Read On The Fox News App
The study noted that the authors were "retained" by Save Local Restaurants but said the research was conducted independently.
Chef Andrew Gruel, a California-based restaurateur, told Fox News Digital he saw early on that there could be negative consequences for the service industry.
"I railed about this months ago," he said, adding that while the early economic effects were being touted, he suggested there would be losses.
Martina Navratilova Takes Shot At Gavin Newsom Over California's Trans-athlete Policy
Gruel also offered advice to businesses struggling to keep up with the minimum wage requirement.
"Cut your menu size, outsource a lot of kitchen labor and utilize AI for back office management," Gruel said.
Social Media Blasts 'Gaslighting' Gavin Newsom After He Announces New Podcast
The minimum wage for workers was $16 before the $20 minimum wage for fast-food workers became law in April 2024. Gov. Gavin Newsom said in September 2023 the increase would help workers earn more as the cost-of-living rises.
"Fast food workers in CA will now be paid the highest minimum wage of any state in the country. I just signed a bill that will ensure these workers receive the fair pay they deserve," he tweeted at the time.
However, the report also cautioned that it may also result in people getting paid less overall and "accelerate automation."
"If large enough, the combination of job eliminations and reductions could leave workers earning less income as a result of (the) $20 minimum wage," the report stated.
"For example, even if no jobs are eliminated (a dubious assumption given the BLS data discussed above), a 20% reduction in hours worked with no overtime increases would erase the financial gains from the 25% hourly wage increase, leaving workers with the same or even less total income," it continued.
The California Fast Food Council may consider increasing the minimum wage to $20.70, according to Restaurant Business Magazine.Original article source: New study reveals blue state's fast-food minimum wage hike jeopardized thousands of jobs
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
25 minutes ago
- Forbes
What The Worst Jobs Report In 15 Years Means For All Americans
Washington DC USA , Sep 03 2019 : Labor sign and building. getty The American job market suffered its worst hit in 15 years (with the exception of Covid); our Denier-in-Chief immediately declared the July Jobs Report 'rigged' by Erika McEntarfer, commissioner of the Bureau of Labor Statistics (BLS) to make him and other Republicans 'look bad;' and Mr. Trump proceeded to tread all over historical objectivity, bipartisan fairness, and professional excellence. President Donald Trump took one look at the report and fired McEntarfer. Trump, in essence, didn't like the message so he took an unprecedented step He shot the messenger. In his rantings and ravings, all of which began only minutes after the report was released, Trump accused McEntarfer of two things: bad reporting and political motivation. This was neither. For the record, there appears to be no other confirmed case in U.S. history of a Senate‑confirmed, cabinet-level official being dismissed specifically for delivering a report with 'bad' news. The Senate confirmed McEntarfer, a Biden pick, by a vote of 86-8, clearly bipartisan, Monthly Jobs Reports have been issued by the BLS ever since 1939, always keeping to the same methodology and protocol. One thousand twenty-/five reports – both good news and bad – have been unassailable, and there is every reason to believe that has continued. Not only were July's numbers – 73,000 jobs created – among the lowest of the last 15 years, but the previous two months were revised sharply downward by a combined 258,000 – May and June to 19K and 14K – yielding in the past three months a level lower than any three-month figure other than Covid's ransacking of the workplace of the past 15 years. These revisions are standard operating procedure, and happen every month. If I were Trump, I'd be upset, too, but not at McEntarfer. A more granular look is alarming. Of the 73,000 jobs, 55,000 came in health care – not a surprise – leaving only 18,000 for the rest of the entire economy. Trump can blame anyone he wants for that but it's still a frightening thing. It is this writer's strong suspicion that these disastrous numbers were self-inflicted and brewing under the surface since Trump's inauguration and immediate creation of DOGE with Elon Musk's chain saw-yielding symbolism. Analysts and observers everywhere – me included – were waiting for this – and it finally hit – with a second shoe certainly looming above and ready to drop. Probably more. The chickens are coming home to roost, all our career readiness and job search strategies are now in play, and the battle is joined.
Yahoo
39 minutes ago
- Yahoo
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
- Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET PASADENA, Calif., August 07, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025, PDUFA date," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "We continue to maintain a strong balance sheet, which we believe gives us the financial resources to move multiple innovative new medicines through the clinical and regulatory process and ultimately get them to the patients who need them." Selected Recent Events Announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead's investigational cardiometabolic candidates in Greater China. Summary terms of the agreement include: Visirna will receive an upfront payment of $130 million from Sanofi. In addition, Visirna will be eligible to receive further milestone payments of up to $265 million upon approval of plozasiran across various indications in mainland China. Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people living with elevated triglycerides. Earned a $100 million milestone payment from Sarepta Therapeutics when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. Arrowhead currently expects to achieve the second enrollment target by the end of 2025, which would trigger an additional $200 million milestone payment from Sarepta. Completed enrollment in investigational plozasiran clinical studies SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously submitted a New Drug Application (NDA) for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the U.S. FDA has accepted with a Prescription Drug User Fee Act (PDUFA) action date set for November 18, 2025. Dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company's investigational RNAi therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease. Zodasiran is the fourth investigational RNAi-based candidate developed by Arrowhead to reach late-stage pivotal studies, after investigational drugs plozasiran, fazirsiran (licensed to Takeda) and olpasiran (licensed to Amgen). Dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNAi therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes. Selected Fiscal 2025 Third Quarter Financial Results ARROWHEAD PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Three Months Ended June 30, OPERATING SUMMARY 2025 2024 (Unaudited) Revenue $ 27,767 $ — Operating Expenses: Research and development 162,368 152,431 General and administrative expenses 30,949 23,710 Total operating expenses 193,317 176,141 Operating loss (165,550 ) (176,141 ) Total other (expense) income (13,539 ) 2,164 Loss before income tax expense and noncontrolling interest (179,089 ) (173,977 ) Income tax (benefit) expense (437 ) — Net loss including noncontrolling interest (178,652 ) (173,977 ) Net loss attributable to noncontrolling interest, net of tax (3,411 ) (3,184 ) Net loss attributable to Arrowhead Pharmaceuticals, Inc. $ (175,241 ) $ (170,793 ) Net loss per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted $ (1.26 ) $ (1.38 ) Weighted-average shares used in calculating - Diluted 139,039 124,199 FINANCIAL POSITION SUMMARY June 30, 2025 September 30, 2024 (unaudited) Cash, cash equivalents and restricted cash $ 129,793 $ 102,685 Available-for-sale securities, at fair value 770,579 578,276 Total cash resources (Cash, cash equivalents and restricted cash and Available-for-sale securities, at fair value) 900,372 680,961 Other current and long-term assets 480,240 458,841 Total Assets $ 1,380,612 $ 1,139,802 Liability related to the sale of future royalties $ 360,254 $ 341,361 Credit Facility 240,332 393,183 Deferred revenue 22,979 — Other liabilities 237,241 214,195 Total Liabilities $ 860,806 $ 948,739 Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity 522,313 185,444 Noncontrolling Interest (2,507 ) 5,619 Total Noncontrolling Interest and Stockholders' Equity $ 519,806 $ 191,063 Total Liabilities, Noncontrolling Interest and Stockholders' Equity $ 1,380,612 $ 1,139,802 Shares Outstanding 138,144 124,376 Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, including the timing of achievement of the next ARO-DM1 milestone, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements, including our ability to achieve such milestones on projected timelines (if at all) and receive timely payment if milestones are achieved; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We disclaim any intention to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. View source version on Contacts Arrowhead Pharmaceuticals, Anzalone, CFA626-304-3400ir@ Investors: LifeSci Advisors, LLCBrian Ritchie212-915-2578britchie@ Media: LifeSci Communications, LLCKendy Guarinoni, Ph.D.724-910-9389kguarinoni@
Yahoo
41 minutes ago
- Yahoo
Disney settles Trump-supporting 'Star Wars' actor lawsuit
A "Star Wars" actor who sued Disney for firing her over inflammatory social media posts about the Holocaust, the pandemic and trans rights has reached a settlement with the Hollywood studio, the entertainment giant announced Thursday. Gina Carano, a prominent Donald Trump supporter who had a major role in the hit Disney+ series "The Mandalorian" until 2021, claimed wrongful termination in a lawsuit filed last year with the backing of billionaire Elon Musk. On Thursday, a spokesperson for Disney subsidiary Lucasfilm said the companies had "reached an agreement with Gina Carano to resolve the issues in her pending lawsuit." Disney "look forward to identifying opportunities to work together with Ms. Carano in the near future," said a statement sent to AFP. Carano, an outspoken former martial arts fighter-turned-actor, was fired by Disney in 2021 for what the company at the time dubbed "abhorrent and unacceptable" social media posts "denigrating people based on their cultural and religious identities." One post shared by Carano appeared to compare being a conservative in the United States to being Jewish in Nazi Germany. "Nazi soldiers could easily round up thousands of Jews" because "the government first made their own neighbors hate them simply for being Jews," the post said. "How is that any different from hating someone for their political views?" it concluded, with a graphic photo of a Jewish woman being beaten in Nazi Germany. Another post appeared to mock a person for wearing multiple masks during the Covid-19 pandemic in California. Carano had earlier enraged members of the trans community for writing on her Twitter profile that her preferred pronouns were "boop/bop/beep." - 'The truth shall set you free' - In her initial lawsuit, Carano said Disney had damaged her reputation and ability to find work in the future, after she had expressed personal political views that led to her being hounded by an "extreme progressive" online mob. The California lawsuit was funded by Musk's X, after Carano publicly replied to an open offer from the tech billionaire to help anyone fired after using his social media platform to exercise free speech. Carano previously claimed she lost a role on a planned "Mandalorian" spin-off called "Rangers of the New Republic" that would have been worth "$150,000 to $250,000 per episode." The Lucasfilm statement said Carano "was always well respected by her directors, co-stars, and staff, and she worked hard to perfect her craft while treating her colleagues with kindness and respect." Carano also supported Donald Trump's recent election campaign, speaking at a campaign rally in Las Vegas last year. Disney has become embroiled in the United States' so-called "culture wars" in recent years. In March, US regulators under the Trump administration announced an investigation into diversity efforts at the Walt Disney Company. Neither Disney nor Carano disclosed the terms of the agreement, but she appeared to allude to the lawsuit's settlement on her social media. "...and the truth shall set you free," Carano posted Thursday on X. amz/hg/jgc
